Global Oxygen Concentrators Industry: 2020 to 2027

The “Oxygen Concentrators – Global Market Trajectory & Analytics” report: Amid the COVID-19 crisis, the global market for Oxygen Concentrators estimated at US$2.5 Billion in the year 2020, is projected to reach a revised size of US$5.3 Billion by 2027, growing at a CAGR of 11.4% over the period 2020-2027.

Portable Oxygen Concentrators, one of the segments analyzed in the report, is projected to record 13.4% CAGR and reach US$3.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Fixed Oxygen Concentrators segment is readjusted to a revised 8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $740.7 Million, While China is Forecast to Grow at 10.8% CAGR

The Oxygen Concentrators market in the U.S. is estimated at US$740.7 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$928.4 Million by the year 2027 trailing a CAGR of 10.9% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10% and 9.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Select Competitors (Total 43 Featured):

  • Chart Industries, Inc.
  • DeVilbiss Healthcare LLC
  • Inogen, Inc.
  • Invacare Corporation
  • Medtronic PLC
  • Nidek Medical Products, Inc.
  • O2 Concepts, LLC
  • Philips Healthcare
  • Teijin Ltd.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Impact of COVID-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 43

For more information about this report visit here.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.